vegf-targeted therapy in hcc: ramucirumab
Published 5 years ago • 101 plays • Length 5:40Download video MP4
Download video MP3
Similar videos
-
5:28
ramucirumab’s role in managing hcc
-
3:58
anti-vegf therapy in metastatic hcc
-
6:42
ramucirumab after progression in advanced hcc
-
0:40
new options for overcoming resistance to anti-vegf therapy in hcc
-
0:45
dr. mcdermott on the role of vegf targeted therapy in rcc
-
1:42
dr. el-khoueiry on the role of ramucirumab in advanced hcc
-
4:10
safety/efficacy experience with ramucirumab in hcc
-
1:41
dr. llovet on reach trials with ramucirumab in hcc
-
2:03
investigating the role of vegf in targeted therapy for cancer
-
1:57
dr. andrew zhu on ramucirumab for hcc
-
3:26
role of vegf tkis for treatment of hcc
-
0:46
dr. abou-alfa on ramucirumab as second-line therapy for hepatocellular carcinoma
-
1:08
dr. llovet discusses second-line ramucirumab in advanced hcc
-
13:46
choosing between vegf and egfr targeted therapy in mcrc
-
58:25
molecular targeted therapies for advanced hcc
-
6:18
treating nsclc with ramucirumab: the revel trial
-
3:58
cyramza® (ramucirumab) mechanism of action in advanced hepatocellular carcinoma (hcc)
-
3:31
vegf targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma
-
1:33
discontinuing vegf-targeted therapy for progression affects second-line therapies in mrcc